US Needs OTC Inhalers For Asthma Treatment, And FDA Should Force A Switch, Researchers Say
Executive Summary
In addition to epinephrine inhaler indicated for emergency use FDA currently allows for nonprescription access, a “positive step forward would be to make inhaled albuterol available OTC,” say researchers in a recent JAMA article.
You may also be interested in...
Amphastar Receives FDA Approval For Regadenoson Following Solid Q1
Amphastar has become the fifth firm to receive FDA approval for generic regadenoson, but the exact launch date for the firm and its other generic competitors remains uncertain.
Expanding Naloxone Access Needs Normalizing First-Aid Use, Keeping Purchase Records Private
Opposition to making naloxone available OTC remains strident because of stigma surrounding drug overdoses, says Bobby Mukkamala, a head and neck surgeon and an AMA Board of Trustees member.
Primatene Mist Drives Amphastar Sales Growth
Amphastar reported double-digit growth in the fourth quarter driven by sales of Primatene Mist, epinephrine products and glucagon. The company also revealed that it is anticipating a Q3 FY22 launch of vasopressin.